First Sofdra prescriptions for excessive sweating condition pushes Botanix towards full commercial launch

The Market Herald12-17

Botanix (ASX:BOT) has reported the first prescriptions of its drug Sofdra (sofpironium) to treat hyperhidrosis, a condition of excessive sweating. According to Botanix, the first prescriptions were ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492671289?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-17 07:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492671289","market":"us","top_or_hot":-1,"title":"First Sofdra prescriptions for excessive sweating condition pushes Botanix towards full commercial launch","media":"The Market Herald","content":"<div>\n<p>Botanix (ASX:BOT) has reported the first prescriptions of its drug Sofdra (sofpironium) to treat hyperhidrosis, a condition of excessive sweating.\nAccording to Botanix, the first prescriptions were ...</p>\n\n<a href=\"https://themarketonline.com.au/first-sofdra-prescriptions-for-excessive-sweating-condition-pushes-botanix-towards-full-commercial-launch-2024-12-17/\">Source Link</a>\n\n</div>\n","source":"markerherald_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>First Sofdra prescriptions for excessive sweating condition pushes Botanix towards full commercial launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFirst Sofdra prescriptions for excessive sweating condition pushes Botanix towards full commercial launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 07:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://themarketonline.com.au/first-sofdra-prescriptions-for-excessive-sweating-condition-pushes-botanix-towards-full-commercial-launch-2024-12-17/><strong>The Market Herald</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Botanix (ASX:BOT) has reported the first prescriptions of its drug Sofdra (sofpironium) to treat hyperhidrosis, a condition of excessive sweating.\nAccording to Botanix, the first prescriptions were ...</p>\n\n<a href=\"https://themarketonline.com.au/first-sofdra-prescriptions-for-excessive-sweating-condition-pushes-botanix-towards-full-commercial-launch-2024-12-17/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BOT.AU","symbol_name":"BOTANIX PHARMACEUTICALS LTD","start_time":0,"source_url":"https://themarketonline.com.au/first-sofdra-prescriptions-for-excessive-sweating-condition-pushes-botanix-towards-full-commercial-launch-2024-12-17/","article_id":"2492671289","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492671289","pubTimestamp":1734391500,"columns":[],"sourceInfo":{"source_id":"markerherald_stock","name":"The Market Herald"},"weMediaInfo":null,"summary":"Botanix  has reported the first prescriptions of its drug Sofdra  to treat hyperhidrosis, a condition of excessive sweating.According to Botanix, the first prescriptions were quickly followed up by the first deliveries of products to patients; the move was also a confirmation of logistics between Botanix, telehealth partners, and its patients.It’s given Botanix the chance to improve marketing and sales materials, per company statements, with a ‘sales force’ engaged and preparing for a launch meeting in late January.The company ultimately pointed to its transition to a revenue-generating company ahead of the “full commercial launch” in Q1 2025.In the company’s eyes, FDA approval was the gamechanger for the stock. And that’s reflected in the company’s share price. On a 1Y basis, BOT shares are up +153%.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certif","collect":0,"end_time":0,"defaultTopTitle":"themarketonline.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BOT.AU":"BOTANIX PHARMACEUTICALS LTD","BK7502":"大麻概念","BK7096":"制药","BK7508":"医药生物股"},"translate_title":"首个针对出汗过多的Sofdra处方推动Botanix全面商业化推出","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BOT.AU":1},"content_text":"Botanix (ASX:BOT) has reported the first prescriptions of its drug Sofdra (sofpironium) to treat hyperhidrosis, a condition of excessive sweating.\nAccording to Botanix, the first prescriptions were quickly followed up by the first deliveries of products to patients; the move was also a confirmation of logistics between Botanix, telehealth partners, and its patients.\nIt’s given Botanix the chance to improve marketing and sales materials, per company statements, with a ‘sales force’ engaged and preparing for a launch meeting in late January.\nThe company ultimately pointed to its transition to a revenue-generating company ahead of the “full commercial launch” in Q1 2025.\n“With less than 10 employees and contractors at the time of Sofdra approval, the Botanix team has now grown to 25,” the healthcare company wrote today.\n“Drawing talent from leading dermatology and specialty pharmaceutical companies in the USA, with an average of over 20 years’ experience, the team is now fully staffed and readying for launch.”\nIn the company’s eyes, FDA approval was the gamechanger for the stock. And that’s reflected in the company’s share price. On a 1Y basis, BOT shares are up +153%. \nBOT last traded at 38cps. \nJoin the discussion: See what HotCopper users are saying about Botanix and be part of the conversations that move the markets. \nThe material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492671289"}